NCT00190333已完成3 期
Evaluation of the Therapeutic Effects of Escitalopram in Pulmonary Hypertension, Either Primary or Associated
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 9
- 主要终点
- To evaluate the efficacy of oral escitalopram at the dosage of 30 mg/day on the 6-minute walking test in patients with pulmonary hypertension
研究概览
简要总结
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of escitalopram (30 mg/day) in two parallel groups (randomization ratio, escitalopram 2/placebo 1).
详细描述
Primary objective: to evaluate the efficacy of oral escitalopram at the dosage of 30 mg/day for 16 weeks on the 6-minute walking test in patients with pulmonary hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who meet all the criteria listed below will be considered for study inclusion:
- •Male or female older than 18 years of age
- •Meeting World Health Organization (WHO) criteria for pulmonary hypertension (mean pulmonary arterial pressure [PAP] > 25 mmHg at rest and pulmonary capillary wedge pressure < 15 mmHg during right heart catheterization):
- •primary pulmonary hypertension (sporadic or familial), or
- •pulmonary hypertension associated with connective tissue diseases, or
- •pulmonary hypertension associated with HIV infection, or
- •pulmonary hypertension associated with use of appetite suppressants or other toxic compounds, or
- •pulmonary hypertension associated with shunting through a congenital heart defect surgically treated
- •Class II or III in the NYHA classification scheme
- •With a 6-minute walking test distance between 40% and 80% of theoretical values (approximately 50 and 480 m)
- •On conventional treatment, with no change in this treatment during the last month preceding the study. Conventional treatment includes calcium antagonists or beraprost.
- •Subject who consents to participate in the study.
排除标准
- •Subjects with any of the following clinical features will not be included in the study:
- •Pulmonary hypertension related to aortic or mitral valve disease, or extrinsic pulmonary vein compression
- •Pulmonary hypertension related to hypoxia from respiratory disease with a total lung capacity < 70% or Tiffeneau index < 60% upon testing within the last 6 months (chronic obstructive lung disease, interstitial disease, sleep apnea syndrome, alveolar hypoventilation, chronic exposure to high altitudes, neonatal lung disease, or alveolar capillary dysplasia)
- •Pulmonary hypertension associated with portal hypertension
- •Pulmonary hypertension secondary to chronic thrombosis and/or embolism (occlusion of the proximal or distal pulmonary arteries by thrombosis)
- •In the 6-minute walking test, inability to walk for 6 minutes, for any reason, or walking distance of less than 50 m
- •Pregnancy, lactation, women of childbearing potential (if needed, effective contraception will be prescribed)
- •History of hypersensitivity to citalopram or to medications structurally related to citalopram
- •Treatment with another investigational drug within the 3 months preceding study inclusion
- •Cardiovascular, hepatic, neurological or endocrine disease that is clinically significant, or any other significant disease that may interfere with the study protocol or with the interpretation of study findings
- •History of drug or alcohol abuse
- •Liver failure (except abnormalities related to the right ventricular failure)
- •Kidney failure
- •Mental status preventing the patient from understanding the nature, objectives, and possible consequences of the study
- •Non stabilized psychiatric disorders
- •Subject unable to comply with protocol-related constraints (e.g., uncooperative, unable to attend follow-up visits, and probably unable to complete the study).
研究组 & 干预措施
A
Active Comparator
干预措施: escitalopram (Drug)
结局指标
主要结局
To evaluate the efficacy of oral escitalopram at the dosage of 30 mg/day on the 6-minute walking test in patients with pulmonary hypertension
时间窗: for 16 weeks
次要结局
- To evaluate the efficacy of escitalopram in improving hemodynamic parameters (right heart catheterization; decision of doing right heart catheterization belonging to the investigators)(after 16 weeks)
- To evaluate the efficacy of escitalopram in improving the New York Heart Association (NYHA) class(after 16 weeks)
- To evaluate the efficacy of escitalopram in improving the dyspnea (visual analog scale)(after 16 weeks)
- To evaluate the efficacy of escitalopram in improving the quality of life(after 16 weeks)
- To evaluate the efficacy of escitalopram in reducing exacerbations of signs or symptoms of the disease that would otherwise require hospital admission or treatment intensification, particularly treatment with bosentan or IV administration of epoprostenol(after 16 weeks)
- To evaluate the safety of escitalopram, alone or on top of associated drugs(after 16 weeks)
研究者
研究点 (9)
Loading locations...
相似试验
进行中（未招募）
3 期
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEHereditary Angioedema (HAE)NCT06669754Pharvaris Netherlands B.V.81
已完成
3 期
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAEHAEHereditary AngioedemaNCT03485911BioCryst Pharmaceuticals121
已完成
3 期
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPGeneralized Pustular PsoriasisNCT05352893Vanda Pharmaceuticals45
进行中（未招募）
3 期
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsPrimary MyelofibrosisMyelofibrosisMyeloproliferative DisordersPost-Polycythemia Vera MyelofibrosisPrimary MyelofibrosisAnemiaMyelofibrosisNCT04717414Celgene313
已完成
3 期
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation StudyFeverLocally AdvancedMetastatic Colorectal CancerNeutropeniaRectal CancerCancerColon CancerColorectal CancerNCT00911170Amgen847